Literature DB >> 11150506

The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41.

Y Xu1, X Zhang, M Matsuoka, T Hattori.   

Abstract

The N- (N36/DP107) and C-terminal peptides (C34/DP178) from two alpha-helical domains of human immunodeficiency virus type 1 (HIV-1) gp41 inhibited HIV infection. A single-round infection using pseudotyped virus clarified that a greater amount of gp41-derived peptides was necessary for the inhibition of R5 virus (ADA) infection than for that of X4 virus (LAI) infection. Furthermore, R5X4 virus (89.6) infection via CCR5 needs more peptides for inhibition than its infection via CXCR4 does. A high sensitivity of X4 virus was partially ascribed to the inhibition of the 12G5 binding to CXCR4 by DP178LAI.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11150506     DOI： 10.1016/s0014-5793(00)02336-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  7 in total

1.  env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.

Authors:  Valery Fikkert; Peter Cherepanov; Kristel Van Laethem; Anke Hantson; Barbara Van Remoortel; Christophe Pannecouque; Erik De Clercq; Zeger Debyser; Anne-Mieke Vandamme; Myriam Witvrouw
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Authors:  Opass Putcharoen; Sun Hee Lee; Timothy J Henrich; Zixin Hu; Jakapat Vanichanan; Eoin Coakley; Wayne Greaves; Roy M Gulick; Daniel R Kuritzkes; Athe M N Tsibris
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

3.  Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection.

Authors:  Yanjie Yi; Lamorris Loftin; Lingshu Wang; Sarah J Ratcliffe; Jesse Isaacman-Beck; Ronald G Collman
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

4.  Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Authors:  Yossef Kliger; Erez Y Levanon
Journal:  BMC Microbiol       Date:  2003-09-21       Impact factor: 3.605

5.  Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype.

Authors:  Elena Pacheco-Martínez; Evangelina Figueroa-Medina; Carlos Villarreal; Germinal Cocho; José L Medina-Franco; Oscar Méndez-Lucio; Leonor Huerta
Journal:  Virol J       Date:  2016-02-16       Impact factor: 4.099

6.  Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.

Authors:  Min Zhuang; Hong Jiang; Yasuhiro Suzuki; Xiaoguang Li; Peng Xiao; Takashi Tanaka; Hong Ling; Baofeng Yang; Hiroki Saitoh; Lianfeng Zhang; Chuan Qin; Kazuo Sugamura; Toshio Hattori
Journal:  Antiviral Res       Date:  2009-02-11       Impact factor: 5.970

7.  Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.

Authors:  Ahidjo Ayouba; Claude Cannou; Marie-Thérèse Nugeyre; Françoise Barré-Sinoussi; Elisabeth Menu
Journal:  Retrovirology       Date:  2008-03-31       Impact factor: 4.602
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.